Literature DB >> 31602095

Auditory and Vestibular Side Effects of FDA-Approved Drugs for Diabetes.

Robert M DiSogra1, Jerry Meece2.   

Abstract

As of September 10, 2019, there were 75 medications (oral/injectable/inhalants) approved by the U.S. Food and Drug Administration for diabetes management: 1 inhalant, 21 oral combinations, 22 injectable, and 31 oral medications (not in combination with any other diabetes drug). This article isolates the auditory and vestibular side effects of those drugs as reported by the drug's manufacturer as well as those side effects that could interfere with a balance assessment. Twenty of the 75 approved medications (26%) could have an auditory-related side effect. Hearing loss and tinnitus are not on the list. Only two, or just 3%, have vertigo and spinning as reported side effects (one each). More than 50% of the drugs will have some effect on a balance assessment. Audiologists who evaluate a patient with diabetes (PWD) are presented with symptoms that could be related to their diabetes medication. Although the manufacturer might report a side effect as rare or as a percentage from their clinical trials subjects, not all PWD will experience these adverse events. Auditory and vestibular side effects do not dominate the diabetes drug side effect list, but, rather, the most reported side effects could impact a balance assessment. The lists that appear in Appendices A and B should serve as a guide for all professionals involved in managing the PWD (i.e., audiologists, otolaryngologists, diabetes educators, pharmacists, optometrists, dentists, etc.). The list also serves as a counseling tool if a communication problem emerges during the progression of the diabetes. © Thieme Medical Publishers.

Entities:  

Keywords:  U.S. Food and Drug Administration; adverse reaction; side effect; type 1 diabetes; type 2 diabetes

Year:  2019        PMID: 31602095      PMCID: PMC6785333          DOI: 10.1055/s-0039-1697645

Source DB:  PubMed          Journal:  Semin Hear        ISSN: 0734-0451


  5 in total

1.  Increased prevalence of early cochlear damage in young patients with type 1 diabetes detected by distortion product otoacoustic emissions.

Authors:  Carla Tomaz Botelho; Sirley Alves da Silva Carvalho; Ivani Novato Silva
Journal:  Int J Audiol       Date:  2014-02-24       Impact factor: 2.117

Review 2.  Revisiting the cochlear and central mechanisms of tinnitus and therapeutic approaches.

Authors:  Arnaud J Noreña
Journal:  Audiol Neurootol       Date:  2015-05-19       Impact factor: 1.854

3.  Hearing loss in children with type 1 diabetes.

Authors:  A Elamin; M Fadlallah; T Tuevmo
Journal:  Indian Pediatr       Date:  2005-01       Impact factor: 1.411

4.  A Brief History of the Development of Diabetes Medications.

Authors:  John R White
Journal:  Diabetes Spectr       Date:  2014-05

Review 5.  Diabetes mellitus as etiological factor of hearing loss.

Authors:  Clícia Adriana S Maia; Carlos Alberto H de Campos
Journal:  Braz J Otorhinolaryngol       Date:  2005-08-02
  5 in total
  1 in total

Review 1.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.